Complications among premature neonates treated with beractant and poractant alfa
- 324 Downloads
To compare the complications among preterm infants treated with two different natural surfactants.
In a randomized clinical trial, 150 preterm infants with Respiratory distress syndrome (RDS) treated with exogenous surfactant, were enrolled in the study. Group A consisted of 79 neonates that received poractant (curosurf). Seventy one newborn infants in group B were treated with beractant (Survanta).
The mean gestational age for group A and B were 29.40±2.90 wk and 29.50±2.73 wk (P=0.82), respectively. The demographic and clinical variables were similar in both groups. The mean duration of intubation (as a primary outcome) was significantly shorter in infants treated with poractant (3.13±1.80 vs 4.06±2.7 days p=0.05). The mean duration of need for oxygen and hospitalization of patients in group A and B were 17.73±22.25 vs 19.14±17.85 days (p=0.67) and 24.89±26.41 vs 29.14±23.54 days (p= 0.32), respectively. There was no significant difference between groups with respect to mortality and morbidity, including pulmonary hemorrhage, intraventricular hemorrhage (IVH), patent ductus arteriosus, sepsis, and bronchopulmonary dysplasia (secondary outcome).
In this study, infants who received poractant had shorter duration of intubation than infants treated with beractant, without any difference in the duration of oxygen therapy or hospitalization. There was no significant superiority of poractant over beractant.
Key wordsPoractant Respiratory distress syndrome Beractant Morbidity
Unable to display preview. Download preview PDF.
- 2.Rodiguez RJ, Martin RJ, Fanaroff AA. Respiratory distress and its management. In Fanaroff AA, Martin RJ, eds. Neonatalperinatal medicine. Disease of the fetus and infant, 8th ed, Philadelphia; Mosby, 2006; 2: 1097–1107.Google Scholar
- 3.Rodiguez RJ, Martin RJ. Exogenous surfactant therapy in newborns. Respir Care Clin N Am 1999; 5: 595–616.Google Scholar
- 4.Suresh GK, Soll RF. Pharmacologic adjuncts II: exogenous surfactant. In Goldsmith JP, Karotkin EH, ed. Assisted ventilation of the neonate, 4th ed. Philadelphia; Saunders, 2003; 329-344.Google Scholar
- 14.Speer CP, Gefeller O, Groneck P et al. Randomized clinical trial of two different treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. Arch Dis Child 1995; 72: P8–P13.Google Scholar
- 16.Ramanthan R, Ramussen MR, Gerstmann D et al. For the North American study group. A randomized, multicenter masked comparison trial of proctant alfa (curosurf) versus beractant (survanta) in the treatment of respiratory distress syndrome in preterm infants. Am J Perinatol 2004; 21: 109–119.CrossRefGoogle Scholar